Get the Stockscreener App
103.67
1.89%
-2.00
After Hours:
104.49
0.82
+0.79%
Axsome Therapeutics Inc stock is traded at $103.67, with a volume of 874.04K.
It is down -1.89% in the last 24 hours and up +0.14% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$105.67
Open:
$105.41
24h Volume:
874.04K
Relative Volume:
1.07
Market Cap:
$5.46B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-15.88
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-6.49%
1M Performance:
+0.14%
6M Performance:
+6.47%
1Y Performance:
+34.04%
1-Day Range:
$103.02
$106.84
1-Week Range:
$103.02
$112.25
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.67 | 5.46B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Investor Alert: Class Action Lawsuits Against General - GlobeNewswire
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire Inc.
Fibromyalgia Treatment Market to Reach $3.88 Billion by 2033 | - openPR.com
Axsome in $570 million loan and revolving credit facility with Blackstone - The Pharma Letter
Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
William Blair Analysts Boost Earnings Estimates for AXSM - MarketBeat
Cubist Systematic Strategies LLC Invests $9.89 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Fairmount Funds Management LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Major Depressive Disorder Market Growth to Accelerate - openPR.com
Axsome Therapeutics enters $570M term loan, credit facility with Blackstone - MSN
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Axsome Therapeutics Enters $570 Million Credit Deal With Blackstone - marketscreener.com
Axsome Therapeutics (AXSM) Secures $570 Million Credit Facility - GuruFocus
Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - Nasdaq
Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - marketscreener.com
3 Monster Stocks in the Making - aol.com
Axsome secures $570 million credit facility from Blackstone - Investing.com
Axsome secures $570 million credit facility from Blackstone By Investing.com - Investing.com Nigeria
Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan - Nasdaq
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - The Manila Times
BNP Paribas Financial Markets Has $15.71 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Northern Trust Corp - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Price T Rowe Associates Inc. MD Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Has Bullish Forecast for AXSM FY2028 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Frontier Capital Management Co. LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% Following Better-Than-Expected Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Estimates By $0.46 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
BVF Inc. IL Has $117.44 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat
Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics at Citizens JMP Life Sciences: Strategic Growth Unveiled - Investing.com India
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):